Biogen Inc at Goldman Sachs Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Great. So Alisha, I mean, you're now -- you've come in to head the US commercial operations. Could we start here given you have three key ongoing launches? Let's start with LEQEMBI. At your last earnings, you noticed an acceleration in patients on drug since the end of last quarter, particularly in March. What were the drivers behind this? And then how do you plan to continue the momentum here?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Help us understand how to think on the forward about the entry of another player and Lilly just had their FDA AdCom panel this week.

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : How are you thinking about the reliability for a third-party script data for tracking the launch just given that we tend to look at that?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Could you provide us a broad update on launch metrics such as the number of patients on drug and on the waiting list, the proportion of top IDNs placing LEQEMBI orders and unique prescribers? And any other signals that we can use to kind of understand and think about the inflection as we watch this launch move along?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : And how is the expansion of the US sales force helping in this effort?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Great. Could you outline the timelines here for the potential regulatory approvals of the IV maintenance and subcutaneous induction and induction and maintenance filings and provide an update to the ex-US expansion strategy here for LEQEMBI?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : And how are you thinking about potential impact from Medicare Part D redesign, maybe help us understand the dynamics here as it relates to the pricing and coverage of the subcutaneous formulation in particular?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Turning to SKYCLARYS in Friedreich's ataxia, could you just provide an update here on the patients on drug in the US and penetration into the addressable populations geographically to date? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 12, 2024 / 2:40PM, BIIB.OQ - Biogen Inc at Goldman Sachs Global Healthcare Conference

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Great. And when you add the need for identification, as you just mentioned, you have to go out and find these patients with rare diseases but also there's compliance and logistical factors that could play out. How do you think this could affect quarterly trends regarding new patient adds on the forward?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Can you comment on the feedback you're getting from real-world experience from these patients?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : And how could label expansion to the pediatric population potentially help here as a lever of growth? Maybe help us understand the magnitude.

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : And on the launches, lastly here with ZURZUVAE. Help us understand the division of responsibilities between yourself and Sage as well as how the early launch metrics are tracking and just your confidence in the outlook here?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Great. And one last question here. What do you believe that investors should be paying attention to outside of these launches as it relates to the base business? And help us in that answer, understand how you think about the margin trajectory in 2025 and beyond, given the cost savings and post the recent deals that you've done, whether there is appetite for more?

Question: Salveen Richter - Goldman Sachs & Co Inc - Analyst : Great. Well, with that, Alisha and Chuck, thank you so much.